MID-1

MID-1 is an inhibitor of IGF-1R used in studies of PI3K-Akt-mTOR Signaling and Protein Degradation / Proteasome. In practice, this places the compound in experiments that measure growth-factor signaling, survival control, and nutrient-sensing outputs and ubiquitin-dependent turnover, proteostasis, and targeted protein degradation in cancer, cell signaling, and metabolism models.

By inhibiting IGF-1R, MID-1 can be used to examine growth-factor signaling, survival control, and nutrient-sensing outputs and ubiquitin-dependent turnover, proteostasis, and targeted protein degradation. The kinase annotation adds relevance to biochemical kinase assays, phospho-signaling studies, and selectivity profiling, together with downstream-response mapping in the same experimental setting. In cancer, cell signaling, and metabolism models, these readouts can be combined with viability, reporter, localization, biochemical conversion, or morphology endpoints to refine experimental interpretation.

Research Applications

• Target-focused assays involving IGF-1R
• Pathway perturbation studies connected to PI3K-Akt-mTOR Signaling and Protein Degradation / Proteasome
• Concentration-response inhibition and target-dependence studies
• Biochemical kinase assays, phospho-signaling studies, and selectivity profiling

Overall, MID-1 is appropriate when a defined chemical perturbant is needed to connect IGF-1R with measurable biochemical, transcriptional, electrophysiological, imaging, or phenotypic readouts in cancer, cell signaling, and metabolism models. This profile is suited to mechanistic follow-up, comparative profiling, and assay optimization under defined exposure conditions.